Skip to main content
Premium Trial:

Request an Annual Quote

Enigma Diagnostics, Partners Snag $4.3M in EU Funding To Develop Rapid Influenza Dx

NEW YORK (GenomeWeb News) - Enigma Diagnostics said today that the RANGER Consortium, an international group of companies and research institutes, has received a €3 million ($4.3 million) award from the European Commission Framework 7 program to develop a portable, rapid PCR-based test to detect influenza infections and subtypes.
 
Enigma, based in Porton Down, UK is the coordinator of the RANGER consortium. Other players include Applied Biosystems, Sagentia, Tico Europe, Bruhn Newtech Group, Bioplastics BV, PERA, the UK’s Health Protection Agency, and the Queen Sirikit National Institute of Child Health.
 
The company said the diagnostic tool will be based on its automated instrumentation, which integrates sample prep with real-time PCR to detect viral RNA in clinical samples.
 
Enigma said it is also separately developing RT-PCR-based diagnostic tests for chlamydia, gonorrhea, and other sexually transmitted infections.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.